09:15:12 EST Mon 11 Nov 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:SLNO - SOLENO THERAPEUTICS INC - http://www.soleno.life
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SLNO - Q4.056.52·59.490.157.050.4225    58.9799  21.3808:04:47Nov 0615 min RT 2¢

Recent Trades - All 5 today
Time ETExPriceChangeVolume
08:04:47Q59.492.441
08:04:30Q59.562.512
08:04:30Q59.562.51100
08:04:30Q59.502.45100
08:04:14Q59.792.741
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-11-06 16:05U:SLNONews ReleaseSoleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
2024-10-28 08:00U:SLNONews ReleaseSoleno Therapeutics to Participate in Upcoming November Investor Conferences
2024-10-21 08:00U:SLNONews ReleaseSoleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D.
2024-10-08 08:30U:SLNONews ReleaseSoleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome
2024-09-16 16:05U:SLNONews ReleaseSoleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference
2024-08-27 08:00U:SLNONews ReleaseSoleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
2024-08-19 16:17U:SLNONews ReleaseSoleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-08-15 08:00U:SLNONews ReleaseSoleno Therapeutics Announces Updates to its Board of Directors
2024-08-07 16:05U:SLNONews ReleaseSoleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
2024-06-28 08:00U:SLNONews ReleaseSoleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome
2024-06-24 17:18U:SLNONews ReleaseSoleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-06-04 08:00U:SLNONews ReleaseSoleno Therapeutics Set to Join Russell 3000(TM) Index
2024-05-22 16:05U:SLNONews ReleaseSoleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
2024-05-22 08:00U:SLNONews ReleaseSoleno Therapeutics to Participate in Upcoming Investor Conferences
2024-05-15 08:00U:SLNONews ReleaseSoleno Therapeutics Stands with the Prader-Willi Syndrome Community
2024-05-09 16:05U:SLNONews ReleaseSoleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
2024-05-02 22:32U:SLNONews ReleaseSoleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
2024-05-02 16:02U:SLNONews ReleaseSoleno Therapeutics Announces Proposed Public Offering of Common Stock
2024-04-30 08:00U:SLNONews ReleaseSoleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome
2024-04-29 08:00U:SLNONews ReleaseSoleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)